Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.460
-0.150 (-5.75%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Xenetic Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
2.52.541.711.160.44
Upgrade
Revenue Growth (YoY)
-1.56%48.80%47.06%165.64%2460.31%
Upgrade
Gross Profit
2.52.541.711.160.44
Upgrade
Selling, General & Admin
3.423.563.653.743.4
Upgrade
Research & Development
3.293.494.773.161.73
Upgrade
Operating Expenses
6.77.068.426.915.13
Upgrade
Operating Income
-4.2-4.52-6.72-5.75-4.69
Upgrade
Interest & Investment Income
0.250.360.170.10.13
Upgrade
Other Non Operating Income (Expenses)
-0.010.03-00-0
Upgrade
EBT Excluding Unusual Items
-3.96-4.13-6.55-5.65-4.57
Upgrade
Asset Writedown
-----9.24
Upgrade
Pretax Income
-3.96-4.13-6.55-5.65-13.81
Upgrade
Income Tax Expense
-----2.92
Upgrade
Net Income
-3.96-4.13-6.55-5.65-10.89
Upgrade
Net Income to Common
-3.96-4.13-6.55-5.65-10.89
Upgrade
Shares Outstanding (Basic)
22111
Upgrade
Shares Outstanding (Diluted)
22111
Upgrade
Shares Change (YoY)
0.86%7.44%38.38%60.81%124.10%
Upgrade
EPS (Basic)
-2.57-2.71-4.61-5.49-17.04
Upgrade
EPS (Diluted)
-2.57-2.71-4.61-5.49-17.04
Upgrade
Free Cash Flow
-2.82-4.11-4.65-4.74-4.27
Upgrade
Free Cash Flow Per Share
-1.83-2.69-3.27-4.61-6.67
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-168.16%-177.78%-393.57%-495.12%-1074.41%
Upgrade
Profit Margin
-158.39%-162.78%-383.87%-486.36%-2493.11%
Upgrade
Free Cash Flow Margin
-112.69%-161.98%-272.23%-408.21%-976.60%
Upgrade
EBITDA
----5.75-4.69
Upgrade
D&A For EBITDA
---00
Upgrade
EBIT
-4.2-4.52-6.72-5.75-4.69
Upgrade
EBIT Margin
-168.16%-177.78%---
Upgrade
Revenue as Reported
2.52.541.711.160.44
Upgrade
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q